DRUG
Bright Minds Biosciences Inc (DRUG)
Healthcare • NASDAQ • $52.40+2.14%
- Symbol
- DRUG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $52.40
- Daily Change
- +2.14%
- Market Cap
- $506.03M
- Trailing P/E
- N/A
- Forward P/E
- -8.96
- 52W High
- $123.75
- 52W Low
- $47.23
- Analyst Target
- $153.35
- Dividend Yield
- 0.00%
- Beta
- 0.23
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the…
Company websiteResearch DRUG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.